JP2016520065A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016520065A5 JP2016520065A5 JP2016513086A JP2016513086A JP2016520065A5 JP 2016520065 A5 JP2016520065 A5 JP 2016520065A5 JP 2016513086 A JP2016513086 A JP 2016513086A JP 2016513086 A JP2016513086 A JP 2016513086A JP 2016520065 A5 JP2016520065 A5 JP 2016520065A5
- Authority
- JP
- Japan
- Prior art keywords
- membered
- sulfur
- ring
- oxygen
- nitrogen
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 31
- 229910052757 nitrogen Inorganic materials 0.000 claims description 26
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims description 22
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 22
- 229910052760 oxygen Inorganic materials 0.000 claims description 22
- 239000001301 oxygen Substances 0.000 claims description 22
- 229910052717 sulfur Inorganic materials 0.000 claims description 22
- 239000011593 sulfur Substances 0.000 claims description 22
- 150000001875 compounds Chemical class 0.000 claims description 20
- 125000005842 heteroatom Chemical group 0.000 claims description 19
- 239000000203 mixture Substances 0.000 claims description 19
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims description 13
- 229920006395 saturated elastomer Polymers 0.000 claims description 13
- 229910052739 hydrogen Inorganic materials 0.000 claims description 12
- 239000001257 hydrogen Substances 0.000 claims description 12
- 229910052736 halogen Inorganic materials 0.000 claims description 11
- 150000002367 halogens Chemical class 0.000 claims description 11
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 9
- 125000002911 monocyclic heterocycle group Chemical group 0.000 claims description 7
- 150000003839 salts Chemical class 0.000 claims description 7
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 6
- 208000008589 Obesity Diseases 0.000 claims description 6
- 150000002431 hydrogen Chemical class 0.000 claims description 6
- 208000030159 metabolic disease Diseases 0.000 claims description 6
- 235000020824 obesity Nutrition 0.000 claims description 6
- 125000001072 heteroaryl group Chemical group 0.000 claims description 5
- 230000002401 inhibitory effect Effects 0.000 claims description 5
- YZCKVEUIGOORGS-OUBTZVSYSA-N Deuterium Chemical compound [2H] YZCKVEUIGOORGS-OUBTZVSYSA-N 0.000 claims description 4
- 125000001931 aliphatic group Chemical group 0.000 claims description 4
- 125000002619 bicyclic group Chemical group 0.000 claims description 4
- 229910052799 carbon Inorganic materials 0.000 claims description 4
- 229910052805 deuterium Inorganic materials 0.000 claims description 4
- 125000000623 heterocyclic group Chemical group 0.000 claims description 4
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 claims description 4
- 125000001620 monocyclic carbocycle group Chemical group 0.000 claims description 4
- 125000006570 (C5-C6) heteroaryl group Chemical group 0.000 claims description 3
- 125000004429 atom Chemical group 0.000 claims description 3
- 239000012472 biological sample Substances 0.000 claims description 3
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 3
- 208000035143 Bacterial infection Diseases 0.000 claims description 2
- 208000008020 Cohen syndrome Diseases 0.000 claims description 2
- 208000032928 Dyslipidaemia Diseases 0.000 claims description 2
- 206010017533 Fungal infection Diseases 0.000 claims description 2
- 208000031226 Hyperlipidaemia Diseases 0.000 claims description 2
- 102000004877 Insulin Human genes 0.000 claims description 2
- 108090001061 Insulin Proteins 0.000 claims description 2
- 208000017170 Lipid metabolism disease Diseases 0.000 claims description 2
- 208000012708 MOMO syndrome Diseases 0.000 claims description 2
- 208000031888 Mycoses Diseases 0.000 claims description 2
- 208000030852 Parasitic disease Diseases 0.000 claims description 2
- CXOFVDLJLONNDW-UHFFFAOYSA-N Phenytoin Chemical compound N1C(=O)NC(=O)C1(C=1C=CC=CC=1)C1=CC=CC=C1 CXOFVDLJLONNDW-UHFFFAOYSA-N 0.000 claims description 2
- 201000010769 Prader-Willi syndrome Diseases 0.000 claims description 2
- 229940100389 Sulfonylurea Drugs 0.000 claims description 2
- 229940123464 Thiazolidinedione Drugs 0.000 claims description 2
- 239000002671 adjuvant Substances 0.000 claims description 2
- 229940125681 anticonvulsant agent Drugs 0.000 claims description 2
- 239000001961 anticonvulsive agent Substances 0.000 claims description 2
- 239000000935 antidepressant agent Substances 0.000 claims description 2
- 229940005513 antidepressants Drugs 0.000 claims description 2
- 239000000164 antipsychotic agent Substances 0.000 claims description 2
- 229940005529 antipsychotics Drugs 0.000 claims description 2
- 125000003118 aryl group Chemical group 0.000 claims description 2
- 208000022362 bacterial infectious disease Diseases 0.000 claims description 2
- 125000005605 benzo group Chemical group 0.000 claims description 2
- 229940124558 contraceptive agent Drugs 0.000 claims description 2
- 239000003433 contraceptive agent Substances 0.000 claims description 2
- 125000001047 cyclobutenyl group Chemical group C1(=CCC1)* 0.000 claims description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 2
- 208000035475 disorder Diseases 0.000 claims description 2
- 229940079593 drug Drugs 0.000 claims description 2
- 239000003814 drug Substances 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- 230000000694 effects Effects 0.000 claims description 2
- 230000003054 hormonal effect Effects 0.000 claims description 2
- 229940125396 insulin Drugs 0.000 claims description 2
- 125000003566 oxetanyl group Chemical group 0.000 claims description 2
- 229960002036 phenytoin Drugs 0.000 claims description 2
- FIADGNVRKBPQEU-UHFFFAOYSA-N pizotifen Chemical compound C1CN(C)CCC1=C1C2=CC=CC=C2CCC2=C1C=CS2 FIADGNVRKBPQEU-UHFFFAOYSA-N 0.000 claims description 2
- 229960004572 pizotifen Drugs 0.000 claims description 2
- 230000002062 proliferating effect Effects 0.000 claims description 2
- AEQFSUDEHCCHBT-UHFFFAOYSA-M sodium valproate Chemical compound [Na+].CCCC(C([O-])=O)CCC AEQFSUDEHCCHBT-UHFFFAOYSA-M 0.000 claims description 2
- 150000003431 steroids Chemical class 0.000 claims description 2
- 208000024891 symptom Diseases 0.000 claims description 2
- 208000011580 syndromic disease Diseases 0.000 claims description 2
- 150000001467 thiazolidinediones Chemical class 0.000 claims description 2
- 229940102566 valproate Drugs 0.000 claims description 2
- 239000003981 vehicle Substances 0.000 claims description 2
- 208000008338 non-alcoholic fatty liver disease Diseases 0.000 claims 2
- 206010053219 non-alcoholic steatohepatitis Diseases 0.000 claims 2
- 102000000452 Acetyl-CoA carboxylase Human genes 0.000 claims 1
- 108010016219 Acetyl-CoA carboxylase Proteins 0.000 claims 1
- 108010018763 Biotin carboxylase Proteins 0.000 claims 1
- 230000005764 inhibitory process Effects 0.000 claims 1
- 238000000034 method Methods 0.000 description 10
- 125000001183 hydrocarbyl group Chemical group 0.000 description 2
- KDLCGRKHKVMFHR-DEOSSOPVSA-N CC(C)(C(N)=O)N(C(c(cc(cc1)-c2ncc[o]2)c1N1C[C@@H](c2cc(F)ccc2OC)OC2CCOCC2)=O)C1=O Chemical compound CC(C)(C(N)=O)N(C(c(cc(cc1)-c2ncc[o]2)c1N1C[C@@H](c2cc(F)ccc2OC)OC2CCOCC2)=O)C1=O KDLCGRKHKVMFHR-DEOSSOPVSA-N 0.000 description 1
- IVABDSKSJOSSRT-DEOSSOPVSA-N CC(C)(C(O)=O)N(C(c(cc(cc1)-c2ncc[o]2)c1N1C[C@@H](c2cc(F)ccc2OC)OC2CCOCC2)=O)C1=O Chemical compound CC(C)(C(O)=O)N(C(c(cc(cc1)-c2ncc[o]2)c1N1C[C@@H](c2cc(F)ccc2OC)OC2CCOCC2)=O)C1=O IVABDSKSJOSSRT-DEOSSOPVSA-N 0.000 description 1
- RHVOBHXRHOANLT-QFIPXVFZSA-N CC(C)(C(O)=O)N(C(c(cc(cc1)Br)c1N1C[C@@H](c2cc(F)ccc2OC)OC2CCOCC2)=O)C1=O Chemical compound CC(C)(C(O)=O)N(C(c(cc(cc1)Br)c1N1C[C@@H](c2cc(F)ccc2OC)OC2CCOCC2)=O)C1=O RHVOBHXRHOANLT-QFIPXVFZSA-N 0.000 description 1
- SOEUICFXQSKRNO-UHFFFAOYSA-N CC(C)(C(O)=O)N(C(c1nc(C(F)(F)F)ccc1N1CC(/C=[O]/C2CCOCC2)c2ccccc2OC)=O)C1=O Chemical compound CC(C)(C(O)=O)N(C(c1nc(C(F)(F)F)ccc1N1CC(/C=[O]/C2CCOCC2)c2ccccc2OC)=O)C1=O SOEUICFXQSKRNO-UHFFFAOYSA-N 0.000 description 1
- QPRWHLAQHYQMQZ-UHFFFAOYSA-N CC(C)(C(O)=O)N(C(c1nc(C2CCC2)ccc1N1CC(/C=[O]/C2CCOCC2)c2ccccc2OC)=O)C1=O Chemical compound CC(C)(C(O)=O)N(C(c1nc(C2CCC2)ccc1N1CC(/C=[O]/C2CCOCC2)c2ccccc2OC)=O)C1=O QPRWHLAQHYQMQZ-UHFFFAOYSA-N 0.000 description 1
- PYXUHQFFTOKVQG-UHFFFAOYSA-N CC(C)/[O]=C(/CN(c(ccc(-c1ncc[o]1)c1)c1C(N1C(C)(C)C(O)=O)=O)C1=O)\c1ccccc1OC Chemical compound CC(C)/[O]=C(/CN(c(ccc(-c1ncc[o]1)c1)c1C(N1C(C)(C)C(O)=O)=O)C1=O)\c1ccccc1OC PYXUHQFFTOKVQG-UHFFFAOYSA-N 0.000 description 1
- FEABGNJLMRLXKO-UHFFFAOYSA-N COc1ccccc1CCN(c(cc1)c(C(N2CC(O)=O)=S)nc1-c1ncc[o]1)C2=S Chemical compound COc1ccccc1CCN(c(cc1)c(C(N2CC(O)=O)=S)nc1-c1ncc[o]1)C2=S FEABGNJLMRLXKO-UHFFFAOYSA-N 0.000 description 1
- UCRIFBCDWXVRAR-UHFFFAOYSA-N COc1ccccc1CCN(c(cc1)c(C(N2CCc3ncc[o]3)=O)nc1-c1ncc[o]1)C2=O Chemical compound COc1ccccc1CCN(c(cc1)c(C(N2CCc3ncc[o]3)=O)nc1-c1ncc[o]1)C2=O UCRIFBCDWXVRAR-UHFFFAOYSA-N 0.000 description 1
- QDKRWQAYFXFZNL-UHFFFAOYSA-N COc1ccccc1CCN(c1c(C(N2CC(O)=O)=O)nc(-c3ncc[o]3)nn1)C2=O Chemical compound COc1ccccc1CCN(c1c(C(N2CC(O)=O)=O)nc(-c3ncc[o]3)nn1)C2=O QDKRWQAYFXFZNL-UHFFFAOYSA-N 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 229940121373 acetyl-coa carboxylase inhibitor Drugs 0.000 description 1
- 230000002293 adipogenic effect Effects 0.000 description 1
- 125000000217 alkyl group Chemical group 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000031146 intracellular signal transduction Effects 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361821831P | 2013-05-10 | 2013-05-10 | |
| US61/821,831 | 2013-05-10 | ||
| PCT/US2014/037370 WO2014182951A1 (en) | 2013-05-10 | 2014-05-08 | Acc inhibitors and uses thereof |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2016520065A JP2016520065A (ja) | 2016-07-11 |
| JP2016520065A5 true JP2016520065A5 (enExample) | 2017-07-06 |
| JP6417403B2 JP6417403B2 (ja) | 2018-11-07 |
Family
ID=51867755
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016513086A Active JP6417403B2 (ja) | 2013-05-10 | 2014-05-08 | Ａｃｃ阻害剤及びその使用 |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US10208044B2 (enExample) |
| EP (1) | EP2994141A4 (enExample) |
| JP (1) | JP6417403B2 (enExample) |
| KR (1) | KR20160005365A (enExample) |
| CN (1) | CN105358155A (enExample) |
| AU (1) | AU2014262547A1 (enExample) |
| BR (1) | BR112015028214A2 (enExample) |
| CA (1) | CA2911822A1 (enExample) |
| CL (1) | CL2015003317A1 (enExample) |
| EA (1) | EA201591962A1 (enExample) |
| HK (2) | HK1221662A1 (enExample) |
| MX (1) | MX2015015416A (enExample) |
| WO (1) | WO2014182951A1 (enExample) |
| ZA (1) | ZA201508355B (enExample) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR112015028173A2 (pt) | 2013-05-10 | 2017-07-25 | Nimbus Apollo Inc | inibidores de acc e usos dos mesmos |
| EP2994139B1 (en) | 2013-05-10 | 2019-04-10 | Gilead Apollo, LLC | Acc inhibitors and uses thereof |
| EP2994138A4 (en) | 2013-05-10 | 2016-12-28 | Nimbus Apollo Inc | ACC-HEMMER AND USES THEREOF |
| WO2015056782A1 (ja) | 2013-10-17 | 2015-04-23 | 塩野義製薬株式会社 | 新規アルキレン誘導体 |
| EA201892625A1 (ru) | 2015-01-09 | 2019-07-31 | Джилид Аполло, Ллс | КОМБИНИРОВАННАЯ ТЕРАПИЯ С ПРИМЕНЕНИЕМ ИНГИБИТОРА АЦЕТИЛ-КоА-КАРБОКСИЛАЗЫ (ACC) ДЛЯ ЛЕЧЕНИЯ НЕАЛКОГОЛЬНОЙ ЖИРОВОЙ БОЛЕЗНИ ПЕЧЕНИ |
| AR106472A1 (es) | 2015-10-26 | 2018-01-17 | Gilead Apollo Llc | Inhibidores de acc y usos de los mismos |
| AU2016361412A1 (en) | 2015-11-25 | 2018-05-24 | Gilead Apollo, Llc | Pyrazole ACC inhibitors and uses thereof |
| MX2018006287A (es) | 2015-11-25 | 2018-09-07 | Gilead Apollo Llc | Inhibidores de acc de triazol y usos de los mismos. |
| ES2943235T3 (es) | 2015-11-25 | 2023-06-12 | Gilead Apollo Llc | Composiciones fungicidas que contienen derivados de 2,4-dioxo-1,4-dihidrotieno[2,3-d]pirimidina |
| KR20180082558A (ko) | 2015-11-25 | 2018-07-18 | 길리어드 아폴로, 엘엘씨 | 에스테르 acc 억제제 및 그의 용도 |
| EP3571205B1 (en) | 2017-01-22 | 2023-08-30 | Sunshine Lake Pharma Co., Ltd. | Thienopyrimidine derivative and use thereof in medicine |
| JP7067725B2 (ja) | 2017-07-17 | 2022-05-16 | ナンジン ルイジエ ファーマテック カンパニー， リミテッド | Ａｃｃ阻害剤としての新規な化合物およびそれらの使用 |
| KR20190036705A (ko) | 2017-09-28 | 2019-04-05 | 한미약품 주식회사 | (2r)-2-(2-메톡시페닐)-2-(옥산-4-일옥시)에탄-1-올 화합물의 신규 제조방법 및 이에 사용되는 중간체 |
| CN110950884B (zh) * | 2018-09-27 | 2024-03-26 | 上海翰森生物医药科技有限公司 | 含二并环类衍生物抑制剂、其制备方法和应用 |
| CN110343650B (zh) * | 2019-05-28 | 2020-12-29 | 浙江工业大学 | 一种产两性霉素b的重组结节链霉菌及其应用 |
| EP3995498A4 (en) | 2019-07-02 | 2023-03-01 | Sunshine Lake Pharma Co., Ltd. | THIENOPYRIMIDINE DERIVATIVES HAVING STEREO CONFIGURATION AND THEIR USE IN MEDICINE |
| AR119594A1 (es) | 2019-08-09 | 2021-12-29 | Gilead Sciences Inc | Derivados de tienopirimidina como inhibidores acc y usos de los mismos |
| US11478533B2 (en) | 2020-04-27 | 2022-10-25 | Novo Nordisk A/S | Semaglutide for use in medicine |
Family Cites Families (39)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR1453897A (fr) | 1965-06-16 | 1966-07-22 | Dérivés du thiophène et de thiéno pyridazines | |
| GB8524663D0 (en) | 1985-10-07 | 1985-11-13 | Fujisawa Pharmaceutical Co | Quinazoline derivatives |
| JPH0747582B2 (ja) * | 1989-12-11 | 1995-05-24 | 杏林製薬株式会社 | キナゾリン―３―アルカン酸誘導体とその塩およびその製造法 |
| US6069298A (en) | 1993-02-05 | 2000-05-30 | Regents Of The University Of Minnesota | Methods and an acetyl CoA carboxylase gene for conferring herbicide tolerance and an alteration in oil content of plants |
| US6303181B1 (en) | 1993-05-17 | 2001-10-16 | Electrochemicals Inc. | Direct metallization process employing a cationic conditioner and a binder |
| GB9817623D0 (en) | 1998-08-13 | 1998-10-07 | Glaxo Group Ltd | Pharmaceutical compounds |
| US6548738B2 (en) | 2000-12-26 | 2003-04-15 | Research Development Foundation | ACC2-knockout mice and uses thereof |
| US6977300B2 (en) | 2001-11-09 | 2005-12-20 | Cv Therapeutics, Inc. | A2B adenosine receptor antagonists |
| US7304070B2 (en) | 2001-11-09 | 2007-12-04 | Cv Therapeutics, Inc. | A2B adenosine receptor antagonists |
| TWI273104B (en) | 2002-06-06 | 2007-02-11 | Eisai Co Ltd | Novel fused imidazole derivative |
| EP1585392B1 (en) * | 2003-01-06 | 2009-03-18 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | Herbicides inhibiting the action of plant acetyl-coa carboxylase for use as pesticides. |
| US7423031B2 (en) | 2003-05-01 | 2008-09-09 | Irm Llc | Compounds and compositions as protein kinase inhibitors |
| CN1871346B (zh) | 2003-06-23 | 2013-05-29 | 先锋高级育种国际公司 | 将单基因控制的保绿潜力工程化进植物中 |
| WO2006014647A2 (en) * | 2004-07-21 | 2006-02-09 | Athersys, Inc. | Cyclic n-hydroxy imides as inhibitors of flap endonuclease and uses thereof |
| JP2006131559A (ja) | 2004-11-05 | 2006-05-25 | Takeda Chem Ind Ltd | 含窒素複素環化合物 |
| EP1912992A1 (en) | 2005-08-10 | 2008-04-23 | SmithKline Beecham Corporation | Xanthine derivatives as selective hm74a agonists |
| CN101384568B (zh) | 2006-02-15 | 2012-12-12 | 雅培制药有限公司 | 乙酰辅酶a羧化酶(acc)抑制剂及其在糖尿病、肥胖症和代谢综合征中的应用 |
| EP1989210A2 (en) | 2006-03-02 | 2008-11-12 | Cv Therapeutics, Inc. | A2a adenosine receptor antagonists |
| NZ574873A (en) | 2006-07-25 | 2012-03-30 | Cephalon Inc | Pyridazinone derivatives as h3 inhibitors |
| TW200823225A (en) | 2006-11-01 | 2008-06-01 | Astrazeneca Ab | New compounds |
| PE20081559A1 (es) | 2007-01-12 | 2008-11-20 | Merck & Co Inc | DERIVADOS DE ESPIROCROMANONA SUSTITUIDOS COMO INHIBIDORES DE ACETIL CoA CARBOXILASA |
| WO2008103354A2 (en) | 2007-02-20 | 2008-08-28 | Cropsolution, Inc. | Modulators of acetyl-coenzyme a carboxylase and methods of use thereof |
| EP2170901B1 (en) | 2007-05-25 | 2015-07-01 | Vertex Pharmaceuticals Incorporated | Modulators of cystic fibrosis transmembrane conductance regulator |
| CN101481380B (zh) | 2008-01-08 | 2012-10-17 | 浙江医药股份有限公司新昌制药厂 | 噻吩并哒嗪类化合物及其制备方法、药物组合物及其用途 |
| EP2291377B1 (en) | 2008-07-02 | 2015-02-18 | Avexa Limited | Imidazopyrimidinones and uses thereof |
| WO2010022236A2 (en) | 2008-08-20 | 2010-02-25 | The University Of Medicine And Dentistry Of New Jersey | Inhibiting obesity progression by inhibiting adipocyte differentiation with a pre-adipocyte autophagy inhibitor |
| EP2351743A4 (en) | 2008-10-27 | 2012-05-09 | Takeda Pharmaceutical | BICYCLIC COMPOUND |
| US20100113473A1 (en) | 2008-10-30 | 2010-05-06 | Player Mark R | Aryl amide compound as an acetyl coenzyme a carboxylase inhibitor |
| WO2010127212A1 (en) | 2009-04-30 | 2010-11-04 | Forest Laboratories Holdings Limited | Inhibitors of acetyl-coa carboxylase |
| US8697739B2 (en) | 2010-07-29 | 2014-04-15 | Novartis Ag | Bicyclic acetyl-CoA carboxylase inhibitors and uses thereof |
| EA201390794A1 (ru) | 2010-11-30 | 2013-11-29 | Такеда Фармасьютикал Компани Лимитед | Бициклическое соединение |
| EA022375B1 (ru) | 2011-04-22 | 2015-12-30 | Пфайзер Инк. | ПРОИЗВОДНЫЕ ПИРАЗОЛОСПИРОКЕТОНОВ ДЛЯ ПРИМЕНЕНИЯ В КАЧЕСТВЕ ИНГИБИТОРОВ АЦЕТИЛ-КоА-КАРБОКСИЛАЗ |
| WO2013035827A1 (ja) | 2011-09-09 | 2013-03-14 | 塩野義製薬株式会社 | 新規オレフィン誘導体 |
| US20130116241A1 (en) | 2011-11-09 | 2013-05-09 | Abbvie Inc. | Novel inhibitor compounds of phosphodiesterase type 10a |
| RS57157B1 (sr) | 2011-11-11 | 2018-07-31 | Gilead Apollo Llc | Acc inhibitori i njihove primene |
| FR2985185B1 (fr) * | 2012-01-04 | 2013-12-27 | Sanofi Sa | Utilisation en therapeutique de derives d'imidazopyridine |
| EP2994139B1 (en) | 2013-05-10 | 2019-04-10 | Gilead Apollo, LLC | Acc inhibitors and uses thereof |
| EP2994138A4 (en) | 2013-05-10 | 2016-12-28 | Nimbus Apollo Inc | ACC-HEMMER AND USES THEREOF |
| BR112015028173A2 (pt) | 2013-05-10 | 2017-07-25 | Nimbus Apollo Inc | inibidores de acc e usos dos mesmos |
-
2014
- 2014-05-08 JP JP2016513086A patent/JP6417403B2/ja active Active
- 2014-05-08 CN CN201480036146.XA patent/CN105358155A/zh active Pending
- 2014-05-08 EP EP14795147.9A patent/EP2994141A4/en not_active Withdrawn
- 2014-05-08 US US14/890,358 patent/US10208044B2/en active Active
- 2014-05-08 EA EA201591962A patent/EA201591962A1/ru unknown
- 2014-05-08 HK HK16109920.8A patent/HK1221662A1/zh unknown
- 2014-05-08 WO PCT/US2014/037370 patent/WO2014182951A1/en not_active Ceased
- 2014-05-08 KR KR1020157035038A patent/KR20160005365A/ko not_active Withdrawn
- 2014-05-08 MX MX2015015416A patent/MX2015015416A/es unknown
- 2014-05-08 HK HK16109662.0A patent/HK1221420A1/zh unknown
- 2014-05-08 CA CA2911822A patent/CA2911822A1/en not_active Abandoned
- 2014-05-08 BR BR112015028214A patent/BR112015028214A2/pt not_active Application Discontinuation
- 2014-05-08 AU AU2014262547A patent/AU2014262547A1/en not_active Abandoned
-
2015
- 2015-11-10 CL CL2015003317A patent/CL2015003317A1/es unknown
- 2015-11-12 ZA ZA2015/08355A patent/ZA201508355B/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2016520065A5 (enExample) | ||
| JP2016520064A5 (enExample) | ||
| JP2016520063A5 (enExample) | ||
| JP2016526024A5 (enExample) | ||
| JP2014533281A5 (enExample) | ||
| JP2018538246A5 (enExample) | ||
| AR103222A1 (es) | Procedimiento para la preparación de análogos de 4-fenil-5-alcoxicarbonil-2-tiazol-2-il-1,4-dihidropirimidina | |
| PE20221584A1 (es) | Derivados carboxi con propiedades antiinflamatorias | |
| CY1120325T1 (el) | Τρικυκλικες ετεροκυκλικες ενωσεις ως αναστολεις φωσφοϊνοσιτιδιου 3-κινασης | |
| JP2016535732A5 (enExample) | ||
| EA201891553A1 (ru) | Ингибиторы syk | |
| JP2019502660A5 (enExample) | ||
| SI3024819T1 (en) | Glyoxamide-substituted pyrrolamide derivatives and their use as medicines for the treatment of hepatitis B | |
| PE20161065A1 (es) | Inhibidores de bromodominio | |
| EA201690094A1 (ru) | Ингибиторы syk | |
| MY176210A (en) | Process for the preparation of n-[(3-aminooxetan-3-yl)methyl]-2-(1,1-dioxo-3,5-dihydro-1,4-benzothiazepin-4-yl)-6-methyl-quinazolin-4-amine | |
| UY33245A (es) | Tienopirimidinas que contienen un grupo alquilo sustituido para composiciones farmacéuticas | |
| AR084174A1 (es) | Compuestos de imidazol-2-benzamida utiles para el tratamiento de osteoartritis y una composicion farmaceutica | |
| EA201790088A1 (ru) | Ингибиторы syk | |
| EA201690012A1 (ru) | Карбазолкарбоксамидные соединения | |
| AR087915A1 (es) | N-(3-(2-amino-6,6-difluor-4,4a,5,6,7,7a-hexahidro-ciclopenta-[e][1,3]oxazin-4-il)-fenil)-amidas como inhibidores de la bace1 | |
| EA201592287A1 (ru) | Замещенные тетрагидрокарбазольные и карбазолкарбоксамидные соединения | |
| AR094876A1 (es) | Derivados de ácido betulínico modificados con alquilo c-3 y alquenilo | |
| CA3015494C (en) | Novel compositions and therapeutic methods | |
| RU2015155585A (ru) | 4-алкинилимидазольное производное и лекарственное средство, включающее такое производное в качестве активного ингредиента |